GO
Loading...

Teva & Barr Get Super-Sized

Friday, 18 Jul 2008 | 1:59 PM ET
The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005.   In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading.  (AP Photo/George Widman)
George Widman
The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005. In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading. (AP Photo/George Widman)

Israel's Teva Pharmaceuticals, the biggest generic drug company in the world, in what became one of the world's worst-kept secrets this week is buying the American Barr Pharmaceuticals.

The price is $66.50 a share, which really isn't much a premium based on Thursday's closing price.

But it's a huge markup from where BRL'sstock was sitting earlier this week before the rumors and media reports started swirling about a deal being in the works.

Barr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.

On the conference call this morning during the question and answer period, one analyst (I'd like to give him credit for his sense of humor, but I can't remember who it was and because I'm under deadline I don't have time to go back and listen to the replay) joked to Mr. Downey, "You got reimbursed for lunch in this deal." The CEO shot back, "And I can afford the next one, too."

I got to know Mr. Downey when he was fighting to win Food and Drug Administration approval of over-the-counter sales for the somewhat controversial Plan B or so-called "Morning After Pill". The social implications of its eventual behind-the-counter approval were much bigger than the financial implications for BRL.

But Mr. Downey maintained he personally believed the drug should be more easily accessible and that he was on a mission to make it happen. In the first quarter of this year, BRL took in nearly 600 million bucks. Less than a hundred million of that was from a number of proprietary products, which includes Plan B.

He also volunteered during his interview with me on CNBC this morning that during his tenure he'd been approached 12 times about doing a deal like this one. A dozen offers! Wow. Both Downey and Yanai said they think the generic drug sector will continue to consolidate. Among the American players still out there are Mylan Labs,Watson Pharmaceuticalsand King Pharmaceuticals, just to name a few.

More Pharma Consolidation Coming
Teva's $7B deal could be just the tip of the consolidation iceberg, with CNBC's Mike Huckman

What's pushing the companies together? Yes, tens of billions of dollars worth of brand-name drugs are going generic. But there are so many generic drug companies around the world that start making the same plain-wrap version of a former blockbuster, prices and profit margins fall even more. And David Maris, who used to cover the sector at Bank of America but now works for a hedge fund, told me over the phone this morning that something new is at work, too.

The likes of Wal-Mart with its $4 generic drug prescriptions and CVS Caremark, which Maris said is now responsible for 20 percent of the drugs purchased in the U.S., are driving hard bargains.

Teva Scoops Up Barr
Generic drug giant Teva Pharmaceuticals bought rival Barr for $7 billion, and some analysts say this could spark a big wave of consolidation. CNBC's Mike Huckman has the details.

Questions? Comments? Pharma@cnbc.com

  Price   Change %Change
MYL
---
ACT
---
CVS
---
WMT
---